SERPINA1 and alpha 1-antitrypsin deficiency: Carriers of other Pi‐genotypes could possibly be managed according to serum AAT levels, with patients exhibiting levels below 50 mg/dL being managed according to the consensus on Pi*ZZ‐related AATD, and those with levels above 50 mg/dL being managed similarly to Pi*MZ and Pi*SZ carriers.